PMID- 19946260
OWN - NLM
STAT- MEDLINE
DCOM- 20100423
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 23
IP  - 2
DP  - 2010 Feb
TI  - Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, 
      parallels low Oncotype DX 21-gene recurrence scores.
PG  - 270-5
LID - 10.1038/modpathol.2009.172 [doi]
AB  - The Oncotype DX assay is one of the molecular tests that provide predictive and 
      prognostic information to breast cancer patients with estrogen receptor 
      (ER)-positive and node-negative disease. This study evaluates the association of 
      Forkhead-box protein A1 (FOXA1) and GATA-binding protein 3 (GATA3) expressions 
      with Oncotype DX recurrences scores in 77 cases of patients with ER-positive 
      node-negative breast carcinomas diagnosed at Indiana University. The data were 
      correlated with patient age, tumor size, histologic type, Scarff-Bloom-Richardson 
      score, histologic grade, and progesterone receptor status. The median FOXA1 and 
      GATA3 scores were 240 and 200, respectively. The Oncotype DX recurrence scores 
      were low in 57%, intermediate in 30%, and high in 13% of cases. FOXA1 expression 
      correlated negatively with Oncotype DX recurrence scores (P=0.004), and 
      histologic type (P=0.0004). Oncotype DX recurrences score also correlated 
      negatively with progesterone receptor (P=0.035) with 100% of progesterone 
      receptor-negative cases having high or intermediate Oncotype DX scores. FOXA1 and 
      GATA3 expressions correlated positively (P=0.014). The correlation between FOXA1 
      expression and Oncotype DX recurrence scores remained significant after adjusting 
      for multiple comparisons and controlling for confounders such as histological 
      type, grade, and progesterone receptor. A statistically significant correlation 
      between the Oncotype DX recurrence scores and FOXA1 expression in our diverse 
      cohort of ER-positive breast cancer patients was observed. We propose that this 
      may represent a more cost-effective strategy to further risk stratify patients 
      with good prognosis in whom chemotherapy may be omitted. To confirm these 
      findings, further studies in a larger cohort of patients are warranted.
FAU - Ademuyiwa, Foluso O
AU  - Ademuyiwa FO
AD  - Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN 
      46202, USA.
FAU - Thorat, Mangesh A
AU  - Thorat MA
FAU - Jain, Rohit K
AU  - Jain RK
FAU - Nakshatri, Harikrishna
AU  - Nakshatri H
FAU - Badve, Sunil
AU  - Badve S
LA  - eng
PT  - Journal Article
DEP - 20091127
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (FOXA1 protein, human)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (GATA3 protein, human)
RN  - 0 (Hepatocyte Nuclear Factor 3-alpha)
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*genetics/*metabolism
MH  - Female
MH  - GATA3 Transcription Factor/*biosynthesis
MH  - Gene Expression
MH  - Gene Expression Profiling
MH  - Hepatocyte Nuclear Factor 3-alpha/*biosynthesis
MH  - Humans
MH  - Immunohistochemistry
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/genetics/metabolism
MH  - Pathology, Molecular/methods
MH  - Prognosis
MH  - Reagent Kits, Diagnostic
EDAT- 2009/12/01 06:00
MHDA- 2010/04/24 06:00
CRDT- 2009/12/01 06:00
PHST- 2009/12/01 06:00 [entrez]
PHST- 2009/12/01 06:00 [pubmed]
PHST- 2010/04/24 06:00 [medline]
AID - S0893-3952(22)02771-5 [pii]
AID - 10.1038/modpathol.2009.172 [doi]
PST - ppublish
SO  - Mod Pathol. 2010 Feb;23(2):270-5. doi: 10.1038/modpathol.2009.172. Epub 2009 Nov 
      27.